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Introduction 
Real-world (RW) evidence is an emerging worldwide paradigm that claims to join the forces of 
academia, research institutes and industry to advance in the field of data science, particularly 
pharmaceuticals [1]. Although appealing, the concept is still controversial so a common, 
technical definition is currently lacking in the literature. According to the ISPOR task force 
report published almost ten years ago [2], RW evidence can be defined as that drawn from 
‘data used for decision making that are not collected in conventional randomized controlled 
trials (RCTs)’. In practice, while RCTs are the acknowledged ‘gold standard’ for efficacy, their 
selected populations, idealized conditions and limited time horizons may be considered 
intrinsic limits to assess effectiveness and costs. 
The sources of RW data can be various [2], the main ones in order of rigor being i) registries 
(prospective observational cohort studies), ii) electronic health records (mainly e-medical 
charts), and iii) administrative databases (typically retrospective data). RW evidence is 
expected to support rational decision-making, especially after market approval of drugs [3]. 
This has recently encouraged regulatory authorities to fast-track drugs to market as soon as 
possible, e.g. the European Medicines Agency through its ‘adaptive licensing’ [4]. Ideally, once 
preliminary efficacy and safety have been assessed, the evaluation of relative effectiveness 
and cost-effectiveness is postponed after marketing approval, relying on RW data for evidence. 
Thus RW sources are potentially vital for economic evaluations (EEs). 
To explore the current state of the art of the subject, we first conducted a literature review of 
European full economic evaluations (EEs) which claimed to be based on RW data, then 
discussed the policy implications from a third-party payer’s perspective. 
RW and Economic Evaluations 
Literature search 
We searched the PubMed international database to select full EEs focused on drugs claimed to 
be based on RW data, published in English from December 2007 until December 2015. We 
used ‘real-world evidence’ and ‘costs OR cost’ as search terms1. The four studies finally 
                                                          
1 From the 210 articles initially identified, 189 were immediately discarded, being: epidemiological and 
clinical studies (103); study protocols (12), studies on methods (12) and of comparative effectiveness 
research (13); economic reviews (15) and other topics (34). Of the remaining 21 EEs, we further 
excluded ten studies not conducted in EU settings, three partial EEs and two EEs not focused on drugs. 
selected [5,6,7,8] came from three countries (Italy, The Netherlands and The UK) and were all 
cost-utility analyses focussed on already marketed drugs and based on Markov models 
conducted from the third-party payer’s viewpoint (Table 1). 
Study-by-study analysis 
In the most recent Dutch study (on follicular lymphoma) [5] the cost-effectiveness of rituximab 
(the sponsored drug) was assessed in different scenarios to match RCT with RW evidence. 
While RCT efficacy and volumes of health care services came from the long-term follow-up of a 
European trial (334 patients), RW effectiveness and resource consumption were mainly 
sourced from two national haematological registries, from which a sample of 113 patients was 
selected. To compare two subgroups of patients (treated and untreated with rituximab), the 
‘propensity score’ method was applied and eventually only 86 patients (43 per subgroup) were 
included in the analysis. Utility values were sourced from a British observational study (cited 
only as a congress abstract). 
The second Dutch study (the only one funded by a public authority) [6] focused on oxaliplatin 
in therapeutic regimens for treating patients in stage III colon cancer. The authors matched 
efficacy from a large multicenter international RCT (1,347 patients) with RW effectiveness from 
a national population-based observational study to obtain different scenarios, by virtually 
splitting RW patients (391) too as eligible or ineligible according to the RCT inclusion criteria. 
Utility values were entirely derived from the literature. Resource consumption for estimating 
costs was taken from the registry mentioned for all scenarios (including that based on RCT 
efficacy). Retrospective RW data led to two unbalanced arms (281 with oxaliplatin versus 110 
without). This was the only study that estimated micro costs in a sample of Dutch hospitals to 
cost hospital services. 
In the Italian study (on HIV infection) [7] the RW data to assess the effectiveness of two 
alternative antiretroviral regimens was derived from a clinical database of a big hospital in 
Lombardy region, but the sample size and patients’ characteristics were not reported. 
Mortality rates were based on national statistics, quality of life was sourced from American 
literature and validated for Italy by an expert panel of ten infectious disease specialists. RW 
resource consumption was taken from the Lombardy region administrative database 
(unknown number of patients in this case too), except for two main side effects from national 
clinical guidelines. 
                                                                                                                                                                          
We finally excluded two EEs since the authors explicitly stated they did not refer to RW data. Thus we 
selected four studies for review and screened them according to a checklist focused on RW sources. 
The British study [8] compared indacaterol (the sponsored drug) with tiotropium and 
salmeterol in patients with COPD. Efficacy and utility were derived from multi-center 
international RCTs on indacaterol, COPD-related mortality rates from a Spanish EE. RW data 
were limited to the resource use of the main health care services and taken from a large 
national survey of 20,001 subjects. One clinical expert validated all resource consumption, 
including that from foreign literature and assumptions for COPD exacerbations. Despite the 
short time horizon (three years), efficacy and costs were both discounted. 
Policy Implications 
RW is a fashionable term that still finds scant application in European EEs according to our 
review. A few recent studies claimed to refer to RW evidence, mostly based on mixed data 
sources and small RW samples. The major apparent contradiction was that, despite RW claims, 
models (mainly long-term) populated by a mix of sources (including expert opinions and 
authors’ assumptions) underpinned all studies reviewed -real ‘patchworks’ like many other 
published EEs [9]. 
In theory, it is obvious to insist that RCTs (especially those for market approval) cannot prove 
effectiveness so EEs based on them should be called cost-efficacy rather than cost-
effectiveness analyses [6]. In practice, however, it is hard to demonstrate effectiveness in RW 
by other means than RCTs, because of the many potential biases mainly generated by lack of 
randomization [3]. Health policy makers have relied on the RCT design for information on 
efficacy with good reason since allocating patients by chance to alternative treatment 
conditions permits an unbiased comparison of treatment differences. In a properly designed 
RCT, any difference observed between the randomised conditions at the end of the trial must 
be due to either the treatment itself or the play of chance, and statistics can assess the extent 
to which the differences have arisen by chance or not. As a consequence, RW evidence-based 
effectiveness is still scant in literature. For instance, an attempt to replicate the findings of 
landmark RCTs in heart failure, using a sophisticated propensity score approach in RW data, 
ended in failure with a massively biased estimate providing a qualitatively opposite (and 
incorrect) result to that found in the RCTs [10]. 
For costs, i.e. the real ‘added value’ of EEs, it is worth recalling that the estimate of each cost 
item is made up of both resource use and unit cost. RW data can only contribute to assessing 
the former, while the latter require different sources by definition [11]. In addition, volumes of 
all cost items are hardly ever available from a single source so more than one is usually 
necessary and models populated with RW data can hardly be an exception. 
Unit costs are the second cost component, as influential as resource consumption in 
estimating real costs and far from realistic in many EEs, starting from drug prices, which are 
becoming increasingly uncertain for both new drugs under confidential agreements [12] and 
mature drugs purchased through tenders [13]. Then too, drastic price reductions thanks to 
generics and biosimilars after patent expiry are hardly ever assumed for already marketed 
drugs, even in long-term models. Besides drugs, the unit costs of hospital services (by far the 
main cost from a third-party payer’s perspective) are usually sourced from (DRG-like) tariffs -
not from micro costs- which are often rough proxies of real costs in many settings, although 
their use provides consistency and comparability of models at a system level. This is 
particularly true in European countries like Italy, where national tariffs are seldom updated 
(twice during the last decade). 
Comment 
To conclude, we are afraid that expectations raised by RW evidence will be unlikely fulfilled in 
the short run for effectiveness and are even compromised in the longer run for costs. 
European regulatory authorities must be aware of these limits and should reconsider the 
present tendency to rely on preliminary efficacy and safety for market approval and on cost-
effectiveness for pricing and reimbursement after launch. We believe they would do better to 
push the pharmaceutical industry from the very start of the approval procedure for new drugs 
to produce evidence on comparative efficacy with those already marketed and therapeutically 
overlapping, then setting prices according to their incremental efficacy (if shown) [14]. 
Otherwise, it is easy to predict that pharmaceutical expenses will become more and more 
unsustainable in most EU countries (wealthy Western ones included) during this (never-
ending) period of economic crisis. 
  
Table 1. Main characteristics of the selected studies and RW data sources 
Variables Blommestein et al, 2014 [5] 
The NL 
van Gils et al, 2013 [6] 
The NL 
Foglia et al, 2013 [7] 
Italy 
Price et al, 2013 [8] 
The UK 
Main 
characteristics 
    
Disease Follicular lymphoma Colon cancer HIV infection COPD 
Alternatives Rituximab mantainance vs. 
second-line chemotherapy 
Oxaliplatin + FPs vs. FPs Lopinavir + ritonavir vs. 
atazanavir + ritonavir 
Indacaterol vs. 
tiotropium/salmeterol 
Type of study  CUA CUA CUA CUA 
Perspective TPP TPP TPP TPP 
Time horizon 20 years lifetime lifetime 3 years 
Modelling Markov Markov Markov Markov 
Conclusion RW data showed that 
rituximab is cost-effective 
Oxaliplatin is cost-effective 
in the adjuvant treatment 
Lopinavir+ritonavir 
dominated 
atazanavir+ritonavir 
Indacaterol dominated 
tiotropium and 
salmeterol 
Sponsorship Yes No Yes Yes 
RW data     
sources 
(sample size) 
Qol - - - - 
Effectiveness Two registries (113) Observational study (391) Hospital records1 - 
Resource 
consumption 
Two registries (113) Observational study (391) Regional administrative 
database1 
Survey (20,001) 
COPD, chronic obustrictive pulmonary disease; CUA, cost-utility analysis; FP, fluoropyrimidine; HIV, human immunodeficiency virus; Qol, quality of life; RW, real world; TPP, third-party 
payer. 
1 Unknown sample size. 
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